For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, treatment options after chemotherapy fails have been essentially nonexistent ...

Targeted protein degradation is changing how drug discovery teams think about disease biology. For many years, small molecule programs were built around inhibition. A compound was expected to bind a ...